Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone.
Elena KurnikovaPavel TrakhtmanDmitriy PershinMariya IlyushinaRimma KhismatullinaMichael MaschanGalina NovichkovaAlexey A MaschanPublished in: Journal of clinical apheresis (2021)
Thus, the safety and high efficacy of plerixafor was proven in healthy pediatric allogeneic hematopoietic cell donors.